Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2017 (2017), Article ID 1096406, 12 pages
https://doi.org/10.1155/2017/1096406
Review Article

The Effect of Hepatosteatosis on Response to Antiviral Treatment in Patients with Chronic Hepatitis B: A Meta-Analysis

Department of Hepatology and Infection, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China

Correspondence should be addressed to Yongfen Zhu

Received 17 December 2016; Accepted 8 February 2017; Published 21 March 2017

Academic Editor: Paul Enck

Copyright © 2017 Yongfen Zhu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Yonghao, X. Jin, L. Jun et al., “An epidemiological serosurvey of hepatitis B virus shows evidence of declining prevalence due to hepatitis B vaccination in Central China,” International Journal of Infectious Diseases, vol. 40, pp. 75–80, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. M. F. Yuen and C. L. Lai, “Treatment of chronic hepatitis B: evolution over two decades,” Journal of Gastroenterology and Hepatology, vol. 26, Supplement 1, pp. 138–143, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. N. Rosso, N. C. Chavez-Tapia, C. Tiribelli, and S. Bellentani, “Translational approaches: from fatty liver to non-alcoholic steatohepatitis,” World Journal of Gastroenterology, vol. 20, no. 27, pp. 9038–9049, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. J. G. Fan, “Epidemiology of alcoholic and nonalcoholic fatty liver disease in China,” Journal of Gastroenterology and Hepatology, vol. 28, no. Supplement 1, pp. 11–17, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. R. Loomba and A. J. Sanyal, “The global NAFLD epidemic,” Nature Reviews Gastroenterology & Hepatology, vol. 10, no. 11, pp. 686–690, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Pais, E. Rusu, D. Zilisteanu et al., “Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease,” European Journal of Internal Medicine, vol. 26, no. 1, pp. 30–36, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. M. M. Wang, G. S. Wang, F. Shen, G. Y. Chen, Q. Pan, and J. G. Fan, “Hepatic steatosis is highly prevalent in hepatitis B patients and negatively associated with virological factors,” Digestive Diseases and Sciences, vol. 59, no. 10, pp. 2571–2579, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. C. W. Lin, X. L. Huang, H. L. Liu, and Y. Wang, “Interactions of hepatitis B virus infection with nonalcoholic fatty liver disease: possible mechanisms and clinical impact,” Digestive Diseases and Sciences, vol. 60, no. 12, pp. 3513–3524, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. Y. L. Wu, X. E. Peng, Y. B. Zhu, X. L. Yan, W. N. Chen, and X. Lin, “Hepatitis B virus X protein induces hepatic steatosis by enhancing the expression of liver fatty acid binding protein,” Journal of Virology, vol. 90, no. 4, pp. 1729–1740, 2016. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Bondini, J. Kallman, A. Wheeler et al., “Impact of non-alcoholic fatty liver disease on chronic hepatitis B,” Liver International, vol. 27, no. 5, pp. 607–611, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. C. C. Wang, T. C. Tseng, and J. H. Kao, “Hepatitis B virus infection and metabolic syndrome: fact or fiction?” Journal of Gastroenterology and Hepatology, vol. 30, no. 1, pp. 14–20, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. G. Wells, B. O. Shea, and D. Connell, The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomized Studies in Meta-analyses, Ottawa (ON), Ottawa Health Research Institute, 2000. View at Publisher · View at Google Scholar
  13. F. Ates, M. Yalniz, and S. Alan, “Impact of liver steatosis on response to pegylated interferon therapy in patients with chronic hepatitis B,” World Journal of Gastroenterology, vol. 17, no. 40, pp. 4517–4522, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Q. Chen, J. M. Wu, J. Chen, Y. Liu, Y. Xu, L. J. Wang et al., “The effect of non-alcoholic fatty liver disease on virologic response in patients with hepatitis B e antigen-positive chronic hepatitis B treated with nucleoside analogues,” Chinese Journal of Infectious Diseases, vol. 32, 2014. View at Google Scholar
  15. Q. G. Cheng, Y. J. Wang, X. Y. Ji, J. Feng, A. L. Li, L. Lin et al., “Efficacy of entecavir therapy for chronic hepatitis B patients; with non-alcoholic fatty liver disease,” Chinese Journal of Clinical Infectious Diseases, vol. 8, 2015. View at Google Scholar
  16. M. Cindoruk, T. Karakan, and S. Unal, “Hepatic steatosis has no impact on the outcome of treatment in patients with chronic hepatitis B infection,” Journal of Clinical Gastroenterology, vol. 41, no. 5, pp. 513–517, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Gong, J. Liu, J. Wang, G. Q. Lou, and J. P. Shi, “Hepatic steatosis as a predictive factor of antiviral effect of pegylated interferon therapy in patients with hepatitis B,” Transplantation Proceedings, vol. 47, no. 10, pp. 2886–2891, 2015, Epub 2015/12/29 View at Publisher · View at Google Scholar · View at Scopus
  18. X. Jin, Y. P. Chen, Y. D. Yang, Y. M. Li, L. Zheng, and C. Q. Xu, “Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B,” PloS One, vol. 7, no. 3, article e34198, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. J. P. Shi, L. Lu, J. C. Qian, J. Ang, Y. H. Xun, J. C. Guo et al., “Impact of liver steatosis on antiviral effects of pegylated interferon-alpha in patients with chronic hepatitis B,” Zhonghua Gan Zang Bing Za Zhi, vol. 20, no. 4, pp. 285–288, 2012. View at Google Scholar
  20. L. Xu, P. Li, Q. Shi, and Y. Mi, “Impact of liver steatosis on the curative effect of pegylated interferon-alpha-2a in patients with chronic hepatitis B,” Zhonghua Gan Zang Bing Za Zhi, vol. 23, no. 2, pp. 99–102, 2015. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Sunbul, “Hepatitis B virus genotypes: global distribution and clinical importance,” World Journal of Gastroenterology, vol. 20, no. 18, pp. 5427–5434, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. R. Zhou, Y. P. Zhou, C. Lin et al., “Baseline prognostic factors and statistic model to predict early virological response in telbivudine-treated patients with chronic hepatitis B,” Hepatitis Monthly, vol. 13, no. 12, article e15573, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. L. B. Yan, E. Q. Chen, L. Bai et al., “Efficacy of entecavir treatment for up to 96 weeks in nucleoside-naive HBeAg-positive chronic hepatitis B patients with high viral load,” Clinics and Research in Hepatology and Gastroenterology, vol. 39, no. 3, pp. 366–372, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. P. Bedossa and T. Poynard, “An algorithm for the grading of activity in chronic hepatitis C. The METAVIR cooperative study group,” Hepatology, vol. 24, no. 2, pp. 289–293, 1996. View at Publisher · View at Google Scholar
  25. D. E. Kleiner, E. M. Brunt, M. Van Natta et al., “Design and validation of a histological scoring system for nonalcoholic fatty liver disease,” Hepatology, vol. 41, no. 6, pp. 1313–1321, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. E. Hashimoto, M. Taniai, and K. Tokushige, “Characteristics and diagnosis of NAFLD/NASH,” Journal of Gastroenterology and Hepatology, vol. 28, Supplement 4, pp. 64–70, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. Chinese Society of H, Chinese Society of Infectious Diseases CMA, “The guideline of prevention and treatment for chronic hepatitis B (2010 version),” Zhonghua Liu Xing Bing Xue Za Zhi, vol. 32, no. 4, pp. 405–415, 2011. View at Google Scholar